Observational studyTranslational psychiatry2025
Brain metabolic vulnerability in 18-F FDG PET/CT predict future depression risk in young cancer survivors.
Observational study in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adolescent and early young adult (AeYA) cancer survivors (aged 15-25 years) face elevated risks of depression following remission. Emerging evidence suggests that brain metabolic vulnerability, detectable via 18-F FDG PET/CT, may serve as a sentinel biomarker for latent depression risk. To investigate this hypothesis, we conducted a multicenter longitudinal study in two independent cohorts (n = 923 discovery, n = 518 validation) in which participants underwent sequential PET/CT scans and were followed for 3 years (mean follow-up: 29.58 ± 10.01 months). Reduced SUVmean values in the ventral prefrontal cortex, hippocampus, and amygdala predominantly predicted future depression onset after adjusting for clinical, psychosocial, and treatment-related confounders. A radiomic nomogram integrating these metabolic parameters demonstrated robust predictive accuracy (C-index: 0.91 discovery, 0.88 validation). By identifying neurobiological susceptibility years before symptom emergence, this study points to 18-F FDG PET/CT as a clinically actionable tool for preemptive depression risk stratification in AeYA survivors, thus repurposing 18F-FDG PET/CT from tumor management surveillance to preemptive depression risk screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.